We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
The current 0N4A market cap is 2.8B. The company's latest EPS is SEK -0.2393 and P/E is -21.77.
| Year End 31 December 2023 | 2020 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| SEK (SEK) | SEK (SEK) | SEK (SEK) | SEK (SEK) | SEK (SEK) | |
| Total Revenue | 201.95M | 2.76M | 68.48M | 4.68M | 9.52M |
| Operating Income | -30.41M | -131.7M | -128.84M | -364.35M | -132.17M |
| Net Income | -10.53M | -140.27M | -132.72M | -365.72M | -128.74M |
| Year End 31 December 2023 | 2020 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| SEK (SEK) | SEK (SEK) | SEK (SEK) | SEK (SEK) | SEK (SEK) | |
| Total Assets | 1.01B | 863.54M | 594.31M | 355.88M | 220.67M |
| Total Liabilities | 185.96M | 183.35M | 44.6M | 30.45M | 22.87M |
| Total Equity | 819.39M | 680.2M | 549.71M | 325.42M | 197.8M |
| Year End 31 December 2023 | 2020 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| SEK (SEK) | SEK (SEK) | SEK (SEK) | SEK (SEK) | SEK (SEK) | |
| Operating | -6.87M | -136.58M | -145.57M | -80.52M | -68.74M |
| Investing | -288.12M | -14.37M | 118.65M | -45.28M | 63.73M |
| Financing | 379.72M | -4.01M | -5.81M | 128.76M | N/A |
| Market Cap | 2.8B |
| Price to Earnings Ratio | -21.77 |
| Price to Sales Ratio | 294.35 |
| Price to Cash Ratio | 651.25 |
| Price to Book Ratio | 14.17 |
| Dividend Yield | - |
| Shares Outstanding | 538.04M |
| Average Volume (1 week) | 0 |
| Average Volume (1 Month) | 0 |
| 52 Week Change | 0.00% |
| 52 Week High | 5.2065 |
| 52 Week Low | 5.2065 |
| Spread (Intraday) | 0.52 (9.46%) |
| Company Name | Oasmia Pharmaceutical Ab |
| Address |
vallongatan 1 uppsala SE-752 28 |
| Website | https://www.vivesto.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
